22. October 2009 07:05
Schering-Plough Corporation (NYSE: SGP) today reported financial results for the 2009 third quarter.
[More]
f483d376-a40f-47e5-be09-6dd38dd1f39b|0|.0
Posted in: Business / Finance
Tags: Anesthesiology, Ankylosing Spondylitis, Antihistamine, Arthritis, Asenapine, Asthma, Brain, Cholesterol, Corticosteroid, Crohn's Disease, Estradiol, Fertility, Generic Drug, Golimumab, Hepatitis C, Influenza, Melanoma, New Drug Application, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Schizophrenia, Ulcerative Colitis, Vaccine, Vicriviroc, Vytorin
20. October 2009 05:35
Phase 3 data reported for the first time show that once every four week subcutaneous injections of SIMPONI(TM) (golimumab) resulted in significantly greater inhibition of structural damage compared with placebo plus methotrexate in patients with active rheumatoid arthritis (RA) and active psoriatic arthritis (PsA).
[More]
fecd05bb-f5de-4327-bddc-9855b00e1fef|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Abatacept, Allergy, Ankylosing Spondylitis, Antibody, Arthritis, Basal Cell Carcinoma, Blood Pressure, Bone, Breast Cancer, Bronchitis, Cancer, Cartilage, Cell, Cold Sores, Cough, Diabetes, Diarrhea, Education, Golimumab, Heart Failure, Hepatitis B, Hodgkin's Disease, Immunology, Inflammatory Disease, Lung Cancer, Lupus, Lymphoma, Methotrexate, Monoclonal Antibody, Multiple Sclerosis, Nausea, Nephrology, Nervous System, Oncology, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Rheumatology, Rituximab, Sepsis, Skin Cancer, Squamous Cell Carcinoma, TNF Blockers, Tuberculosis, Vaccine, Virus, Vomiting, Weight Loss
19. October 2009 09:41
New long-term data from two pivotal, Phase 3 clinical trials showed that patients with active rheumatoid arthritis (RA) receiving SIMPONI(TM) (golimumab) every four weeks achieved sustained improvements in signs and symptoms and physical function response through one year. These new data were presented today at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting.
[More]
c732a27a-bf6d-438e-85d8-c315df6be186|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Adalimumab, Ankylosing Spondylitis, Antibody, Arthritis, Blood Pressure, Breast Cancer, Bronchitis, Cancer, Cartilage, Cell, Cold Sores, Cough, Diabetes, Diarrhea, Education, Etanercept, Golimumab, Heart Failure, Hepatitis B, Hygiene, Immunology, Infliximab, Lupus, Lymphoma, Methotrexate, Monoclonal Antibody, Multiple Sclerosis, Nausea, Nephrology, Nervous System, Oncology, Psoriatic Arthritis, Rheumatoid Arthritis, Rheumatology, TNF Blockers, Tuberculosis, Vaccine, Virus, Vomiting, Weight Loss
13. October 2009 08:07
Johnson & Johnson today announced sales of $15.1 billion for the third quarter of 2009, a decrease of 5.3% as compared to the third quarter of 2008. Operational results declined 2.8% and the negative impact of currency was 2.5%. Domestic sales declined 8.1%, while international sales declined 2.5%, reflecting operational growth of 2.4% and a negative currency impact of 4.9%.
[More]
8c6ce202-17d8-44a3-89cc-c43686b2d777|0|.0
Posted in: Business / Finance
Tags: Ankylosing Spondylitis, Antipsychotic, Arthritis, Diabetes, Emtricitabine, Fentanyl, Golimumab, Immunotherapy, Infliximab, Influenza, Investment, Migraine, Multiple Myeloma, New Drug Application, Paliperidone Palmitate, Psoriasis, Psoriatic Arthritis, Reminyl, Rheumatoid Arthritis, Schizophrenia, Spine, Sports Medicine, Stent, Tenofovir, Truvada
30. September 2009 05:47
Reportlinker.com announces that a new market research report is available in its catalogue: Reportlinker Adds Monoclonal Antibody Therapeutics 2009-2024
[More]
e4f24084-1904-4e9b-97a4-916fa8fa9036|0|.0
Posted in: Device / Technology News
Tags: Antibody, Asthma, Avastin, Bone, Cancer, Cell, Denosumab, Genetics, Golimumab, Head and Neck Cancer, Immunology, MabThera, Monoclonal Antibody, Multiple Sclerosis, Oncology, Ophthalmology, Pfizer, Raptiva, Rituximab, Vectibix, Zevalin
28. June 2009 21:37
Golimumab, a new tumour necrosis factor-α (TNF-α) inhibitor reduces the signs and symptoms of rheumatoid arthritis in patients who have previously received any other TNF-α inhibitor, and might be a good option for patients who have inadequate responses to one or two other TNF-α inhibitors, finds an Article published Online first and in this week's edition of The Lancet.
[More]
13. April 2009 21:20
Centocor Ortho Biotech Inc. and Schering-Plough Corporation has announced that Health Canada has granted approval of Simponi (golimumab) as a once-monthly, subcutaneous therapy for the treatment of moderately to severely active rheumatoid arthritis (RA), active psoriatic arthritis (PsA) and active ankylosing spondylitis (AS).
[More]
ea780d71-9355-4706-9716-c74ce482aaa3|0|.0
Posted in: Pharmaceutical News
Tags: Ankylosing Spondylitis, Antibody, Arthritis, Back Pain, Biologics Drug / Agent, Cartilage, Golimumab, Immunology, Inflammatory Disease, Methotrexate, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Rheumatology, Spine, TNF Blockers
8. April 2009 13:21
Psoriatic arthritis affects about 11 percent of patients with psoriasis.
[More]
477d437c-35cf-4514-8b8e-06cd4db82661|0|.0
Posted in: Drug Trial News
Tags: Antibody, Anti-Inflammatory, Arthritis, Biologics Drug / Agent, Golimumab, Psoriasis, Psoriatic Arthritis, Rheumatism, Rheumatoid Arthritis, Rheumatology, TNF Blockers
Subscribe